Odisha-based IMGENEX India Pvt. Ltd. announces its endevour to develop a potential vaccine against COVID-19
Bhubaneswar: COVID-19 pandemic has resulted in world-wide economic and social havoc. There is an urgent need for diagnostic kits, therapy and vaccines.
IMGENEX India is proud to announce that in its endevour to develop a potential vaccine against COVID-19, using IMGENEX India’s proprietary software and molecular biology technology, we have selected few viral structural proteins which show potential in preliminary assays for COVID-19 inhibition. We are seeking for collaborators with laboratories having capabilities to handle animal model of SARS-CoV2 virus. In addition, we are developing monoclonal antibodies against a conserve region of SARS-CoV2 protein that may act as neutralizing antibodies against not only this novel Coronavirus, but also against SARS and other coronaviruses like Middle Eastern Respiratory Syndrome (MERS).
“We feel the release of this announcement will enhance collaboration of IMGENEX India with laboratories with pathogenic virus and animal handling. We recognize that working together we can develop an indigenous vaccine within 18-24 months”, said Sujay Singh, Ph.D., CEO of IMGENEX India Pvt. Ltd.